Defining Breadth of Hepatitis C Virus Neutralization

Extraordinary genetic diversity is a hallmark of hepatitis C virus (HCV). Therefore, accurate measurement of the breadth of antibody neutralizing activity across diverse HCV isolates is key to defining correlates of immune protection against the virus, and essential to guide vaccine development. Pan...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 9; p. 1703
Main Authors Kinchen, Valerie J, Bailey, Justin R
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 02.08.2018
Subjects
antibodies
Flaviviridae
hepatitis C virus
Immunology
neutralizing breadth
viral diversity
hepatitis C virus
antibodies
viral diversity
Flaviviridae
neutralizing breadth
Online AccessGet full text

Cover

More Information
Summary:Extraordinary genetic diversity is a hallmark of hepatitis C virus (HCV). Therefore, accurate measurement of the breadth of antibody neutralizing activity across diverse HCV isolates is key to defining correlates of immune protection against the virus, and essential to guide vaccine development. Panels of HCV pseudoparticle (HCVpp) or replication-competent cell culture viruses (HCVcc) can be used to measure neutralizing breadth of antibodies. These assays have been used to define neutralizing breadth of antibodies in serum, to characterize broadly neutralizing monoclonal antibodies, and to identify mechanisms of HCV resistance to antibody neutralization. Recently, larger and more diverse panels of both HCVpp and HCVcc have been described that better represent the diversity of circulating HCV strains, but further work is needed to expand and standardize these neutralization panels.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Joseph Torresi, University of Melbourne, Australia; Jonathan Ball, University of Nottingham, United Kingdom
Specialty section: This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
Edited by: Steven Foung, Stanford University, United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2018.01703